Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Treasury Shares: 2010-2025

Historic Treasury Shares for BIO-TECHNE (TECH) over the last 2 years, with Jun 2025 value amounting to $831,000.

  • BIO-TECHNE's Treasury Shares rose 67.20% to $831,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $831,000, marking a year-over-year increase of 67.20%. This contributed to the annual value of $831,000 for FY2025, which is 67.20% up from last year.
  • As of Q2 2025, BIO-TECHNE's Treasury Shares stood at $831,000, which was up 67.20% from $497,000 recorded in Q2 2024.
  • BIO-TECHNE's 5-year Treasury Shares high stood at $1.4 million for Q4 2023, and its period low was $120,000 during Q1 2021.
  • For the 3-year period, BIO-TECHNE's Treasury Shares averaged around $752,000, with its median value being $664,000 (2024).
  • Its Treasury Shares has fluctuated over the past 5 years, first slumped by 56.99% in 2021, then surged by 383.33% in 2022.
  • Over the past 5 years, BIO-TECHNE's Treasury Shares (Quarterly) stood at $357,000 in 2021, then fell by 20.94% to $222,000 in 2022, then dropped by 6.29% to $1.4 million in 2023, then surged by 75.62% to $497,000 in 2024, then surged by 67.20% to $831,000 in 2025.
  • Its last three reported values are $831,000 in Q2 2025, $497,000 for Q2 2024, and $1.4 million during Q4 2023.